These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 29687784

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
    Armada L, Marotta Pdos S, Pires FR, Siqueira JF.
    J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
    [Abstract] [Full Text] [Related]

  • 4. Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.
    Kelesidis T, Currier JS, Yang OO, Brown TT.
    AIDS Rev; 2014 Aug; 16(3):123-33. PubMed ID: 25102334
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ, Ji ZL, Chen SM.
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W, Zhang X.
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [Abstract] [Full Text] [Related]

  • 13. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity.
    Venuraju SM, Yerramasu A, Corder R, Lahiri A.
    J Am Coll Cardiol; 2010 May 11; 55(19):2049-61. PubMed ID: 20447527
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
    Bayer CM, Beckmann MW, Fasching PA.
    Curr Opin Obstet Gynecol; 2017 Feb 11; 29(1):4-11. PubMed ID: 28002265
    [Abstract] [Full Text] [Related]

  • 16. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.
    Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G.
    Expert Rev Cardiovasc Ther; 2006 Nov 11; 4(6):801-11. PubMed ID: 17173497
    [Abstract] [Full Text] [Related]

  • 17. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
    Chen T, Feng X.
    Assay Drug Dev Technol; 2006 Aug 11; 4(4):473-82. PubMed ID: 16945019
    [Abstract] [Full Text] [Related]

  • 18. New insights into osteoclastogenic signaling mechanisms.
    Nakashima T, Hayashi M, Takayanagi H.
    Trends Endocrinol Metab; 2012 Nov 11; 23(11):582-90. PubMed ID: 22705116
    [Abstract] [Full Text] [Related]

  • 19. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
    Park HS, Lee A, Chae BJ, Bae JS, Song BJ, Jung SS.
    J Surg Oncol; 2014 Dec 11; 110(7):807-12. PubMed ID: 25111682
    [Abstract] [Full Text] [Related]

  • 20. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
    Vega D, Maalouf NM, Sakhaee K.
    J Clin Endocrinol Metab; 2007 Dec 11; 92(12):4514-21. PubMed ID: 17895323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.